Ask HopeStage to review this study with me
Study ID: NCT05117632. We help you review the study, but cannot decide medical eligibility.
CompletedNCT05117632
An Study of ALTO-100 in Adults With Major Depressive Disorder and/or PTSD
This study is completed in the United States. It is testing ALTO-100 for depression.
PTSD, DepressionDrugFrom 18 Years to 69 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 23 sites
- Site 136Tempe, ArizonaSite status: Not listed — confirm with the team
- Site 139Little Rock, ArkansasSite status: Not listed — confirm with the team
- Site 141Costa Mesa, CaliforniaSite status: Not listed — confirm with the team
- Site 118Fresno, CaliforniaSite status: Not listed — confirm with the team
- Site 116Martinez, CaliforniaSite status: Not listed — confirm with the team
- Site 116Mather, CaliforniaSite status: Not listed — confirm with the team
- Site 150Boca Raton, FloridaSite status: Not listed — confirm with the team
- Site 112Doral, FloridaSite status: Not listed — confirm with the team
- Site 155Elgin, IllinoisSite status: Not listed — confirm with the team
- Site 137Noblesville, IndianaSite status: Not listed — confirm with the team
- Site 151Baltimore, MarylandSite status: Not listed — confirm with the team
- Site 109Belmont, MassachusettsSite status: Not listed — confirm with the team
- Site 108Jackson, MississippiSite status: Not listed — confirm with the team
- Site 142Lincoln, NebraskaSite status: Not listed — confirm with the team
- Site 144Las Vegas, NevadaSite status: Not listed — confirm with the team
- Site 146Middleburg Heights, OhioSite status: Not listed — confirm with the team
- Site 147Fort Worth, TexasSite status: Not listed — confirm with the team
- Site 148Fort Worth, TexasSite status: Not listed — confirm with the team
- Site 120Houston, TexasSite status: Not listed — confirm with the team
- Site 113Houston, TexasSite status: Not listed — confirm with the team
- Site 121Draper, UtahSite status: Not listed — confirm with the team
- Site 105Seattle, WashingtonSite status: Not listed — confirm with the team
- NTC Seattle (105a)Tacoma, WashingtonSite status: Not listed — confirm with the team
Key information made simple
What is this study testing?
This study is testing whether ALTO-100 may be useful for adults experiencing ptsd.
What would participation involve?
Participants may receive ALTO-100, attend study visits with the research team. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with ptsd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: December 20, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 245
- Sponsor
- Alto Neuroscience
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 69 Years
- Official registry ID
- NCT05117632
- Official title
- An Open-label Study of ALTO-100 in Adults With Major Depressive Disorder and/or Post-traumatic Stress Disorder
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT05117632. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving ALTO-100 PO tablet. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with ptsd; age range: From 18 Years to 69 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Alto Neuroscience, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT03039192
Intranasal Esketamine for depression
This study is completed in the United States, in Bulgaria, in Estonia, .... It is testing intranasal Esketamine for depression.
CompletedNCT03097133
Intranasal Esketamine for depression
This study is completed in the United States, in France, in Canada, .... It is testing intranasal Esketamine for depression.
CompletedNCT01861847
7-Keto DHEA for PTSD
This study is completed. It focuses on PTSD and currently lists study information in the United States.